Literature DB >> 31409596

The Association of Fenofibrate with Kidney Tubular Injury in a Subgroup of Participants in the ACCORD Trial.

Kinsuk Chauhan1, Girish N Nadkarni1, Neha Debnath1, Lili Chan1, Aparna Saha1, Amit X Garg2,3, Chirag R Parikh4, Steven G Coca5.   

Abstract

Entities:  

Keywords:  Fenofibrate; Kidney Tubular Injury; Urine Biomarkers; hypolipidemic agents; kidney

Mesh：

Substances：

Year:  2019        PMID： 31409596      PMCID： PMC6777587          DOI： 10.2215/CJN.00370119

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  5 in total

1.  Effect of Intensive Blood Pressure Lowering on Kidney Tubule Injury: Findings From the ACCORD Trial Study Participants.

Authors:  Girish N Nadkarni; Kinsuk Chauhan; Veena Rao; Joachim H Ix; Michael G Shlipak; Chirag R Parikh; Steven G Coca
Journal:  Am J Kidney Dis       Date:  2018-10-02       Impact factor: 8.860

2.  Effects of Intensive Blood Pressure Lowering on Kidney Tubule Injury in CKD: A Longitudinal Subgroup Analysis in SPRINT.

Authors:  Rakesh Malhotra; Timothy Craven; Walter T Ambrosius; Anthony A Killeen; William E Haley; Alfred K Cheung; Michel Chonchol; Mark Sarnak; Chirag R Parikh; Michael G Shlipak; Joachim H Ix
Journal:  Am J Kidney Dis       Date:  2018-10-02       Impact factor: 8.860

Review 3.  Effects of fibrates in kidney disease: a systematic review and meta-analysis.

Authors:  Min Jun; Bin Zhu; Marcello Tonelli; Meg J Jardine; Anushka Patel; Bruce Neal; Thaminda Liyanage; Anthony Keech; Alan Cass; Vlado Perkovic
Journal:  J Am Coll Cardiol       Date:  2012-10-17       Impact factor: 24.094

4.  Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.

Authors:  Amy K Mottl; John B Buse; Faramarz Ismail-Beigi; Ronald J Sigal; Carolyn F Pedley; Vasilios Papademetriou; Debra L Simmons; Lois Katz; Josyf C Mychaleckyj; Timothy E Craven
Journal:  Clin J Am Soc Nephrol       Date:  2018-10-25       Impact factor: 8.237

5.  Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants.

Authors:  Josyf C Mychaleckyj; Timothy Craven; Uma Nayak; John Buse; John R Crouse; Marshall Elam; Kent Kirchner; Daniel Lorber; Santica Marcovina; William Sivitz; Joann Sperl-Hillen; Denise E Bonds; Henry N Ginsberg
Journal:  Diabetes Care       Date:  2012-03-19       Impact factor: 19.112
  5 in total
  4 in total

Review 1.  Management of Presumed Acute Kidney Injury during Hypertensive Therapy: Stay Calm and Carry on?

Authors:  Teresa K Chen; Chirag R Parikh
Journal:  Am J Nephrol       Date:  2020-01-15       Impact factor: 3.754

2.  Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD.

Authors:  João Pedro Ferreira; Francisco Vasques-Nóvoa; Diana Ferrão; Francisca Saraiva; Inês Falcão-Pires; João Sérgio Neves; Abhinav Sharma; Patrick Rossignol; Faiez Zannad; Adelino Leite-Moreira
Journal:  Diabetes Care       Date:  2022-07-07       Impact factor: 17.152

3.  Use of nephrotoxic medications in adults with chronic kidney disease in Swedish and US routine care.

Authors:  Alessandro Bosi; Yunwen Xu; Alessandro Gasparini; Björn Wettermark; Peter Barany; Rino Bellocco; Lesley A Inker; Alex R Chang; Mara McAdams-DeMarco; Morgan E Grams; Jung-Im Shin; Juan J Carrero
Journal:  Clin Kidney J       Date:  2021-10-29

Review 4.  Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?

Authors:  Jean-Charles Fruchart; Michel P Hermans; Jamila Fruchart-Najib
Journal:  Curr Atheroscler Rep       Date:  2020-07-15       Impact factor: 5.113
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.